Keywords: Theravance, Alfa Wasserman, Velusetrag, Motility disorders, RuiYi, arGEN-X, ARGX109, Inflammatory diseases, Cancer indications

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb

Article | 05 October 2012

USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive development and commercialization agreement in certain ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

arGEN-X

RuiYi

Theravance

Alfa Wassermann

Go to company listing

Related Drugs

velusetrag

ARGX-109

Go to drug listing